FDA Approves Nerivio for Migraine Treatment in Children Aged 8 Years and Older
By Lori Solomon HealthDay Reporter
FRIDAY, Nov. 22, 2024 -- The U.S. Food and Drug Administration has expanded the age indication for Nerivio, making it the first and only remote electrical neuromodulation (REN) wearable for migraine treatment for children aged 8 years and older.
The approval marks the first FDA-cleared, nondrug therapy for acute treatment of migraine in children and the only prescribed preventive treatment of migraine for children in this age group.
The approval is based on real-world data showing the safety and efficacy of REN for migraine treatment in children aged 6 to 11 years. Two hours posttreatment, participants reported significant pain relief and functional disability relief, with no adverse events.
"The options for treating migraine in children under 12, especially ones that are safe, drug-free, and can be used for both acute and preventive treatment, have been very limited until now," Alon Ironi, CEO and cofounder of Theranica, said in a statement. "The expanded age indication offers a much-needed solution for children, especially those who are struggling with side effects from the traditionally prescribed drugs that were not designed nor formally indicated for young patients."
Expanded approval of Nerivio was granted to Theranica.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Endolymphatic Sac Decompression Effective for Vertigo, Migraine
WEDNESDAY, May 28, 2025 -- For Meniere disease (MD) patients with migraine, endolymphatic sac decompression (ELSD) is effective, providing postoperative relief of vertigo and...
No Increase Seen in Neurodevelopmental Disorders With Prenatal Triptan Use
WEDNESDAY, May 21, 2025 -- Children prenatally exposed to different triptan intensities and duration, alone or in combination with other preventive medications for migraine, do...
Ubrogepant During Prodromal Phase of Migraine Eases Symptoms
TUESDAY, May 13, 2025 -- Ubrogepant during the prodromal phase of migraine may alleviate common prodromal symptoms, according to a study published online May 12 in Nature...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.